dsm-firmenich has secured European market access for its 3-fucosyllactose (3-FL) ingredient, one of the most abundant human milk oligosaccharides (HMO) in human milk.
A systematic review of dozens of studies has revealed that levels of the five most prevalent HMOs in breast milk vary widely, and infant formula development should accommodate this variability.
Chr. Hansen and Nestlé have settled a legal dispute involving alleged infringements on Human Milk Oligosaccharide (HMO) patents arising from October 2020’s acquisition of Jennewein Biotechnologie.
Specific strains of probiotic Bifidobacterium and Lactobacillus bacteria given to preterm babies in combination with breast milk may help to build microbial populations and gut health that mirror those of full-term babies, suggests data from the Baby-Associated...
The European Commission (EC) is to allow lacto-N-tetraose (LNT) to be placed on the market as a Novel Food for use in food supplements and infant product formulations.
